What Does a CK5/6 Positive Result Mean?

A CK5/6 positive result means a lab stain found a particular structural protein inside the cells of your biopsy. It is not a cancer test, and by itself it says neither “cancer” nor “no cancer.” The same positive result can be reassuring in one organ and simply descriptive in another, so the organ named on your report decides what it means.

What CK5/6 Is and Why Your Pathologist Tested It

Cytokeratins are fibers that form the internal scaffolding of lining cells. CK5 and CK6 are found mainly in skin and in squamous linings such as the mouth and esophagus, squamous meaning flat, layered, skin-like cells.¹ They also appear in basal cells, the bottom layer that supports glands in the breast, prostate and salivary glands.² In the airways they mark basal cells too, and they are found in the lining cells of the bladder.³

The test is immunohistochemistry, often written IHC on reports. An antibody tagged with a dye is applied to a thin slice of your biopsy. Cells containing CK5/6 turn brown under the microscope, and the report calls them positive. Reports may also describe how many cells stained and in what pattern, not just yes or no.⁴ Positive only means the protein was detected. It is not a verdict on the biopsy as a whole, and it is not like a positive pregnancy or infection test. Negative means the protein was not seen, and whether that is good or bad news depends on what the pathologist was checking for.

Pathologists first study the tissue under the microscope using a routine pink-and-purple stain. They add special stains only when the shapes of the cells leave a question open. The question is usually narrow, such as whether a growth is benign or cancerous, or which type of cancer it is, so ordering the stain does not mean the doctor suspects the worst.

CK5/6 is almost always ordered in a panel with other stains such as p63, ER or TTF-1, because a single stain answers only a narrow question, like “are basal cells present?” The final diagnosis line on your report outweighs any individual stain result. On the report itself, look for a section labeled “immunohistochemistry” or “ancillary studies.” Words like “diffuse,” “focal,” “patchy” or “mosaic” describe how much and where the stain appeared.

CK5/6 Positive in a Breast Biopsy

Some benign breast overgrowths look much like early cancer under the microscope. A common benign overgrowth of duct cells stains strongly and diffusely for CK5.⁵ In contrast, 96% of atypical hyperplasia and low-grade ductal carcinoma in situ cases were negative or only patchily positive.⁶ In another study, all benign hyperplasias stained strongly while a solid type of ductal carcinoma in situ did not.⁷ The reason is that the benign growth keeps a mix of cell types like normal breast, while atypia and early cancer become one uniform type that lacks CK5.⁸

Treatment differs a great deal across benign overgrowth, atypical hyperplasia and early cancer, from simple follow-up to surgery, so pathologists want extra evidence before choosing a label. CK5/6 helps separate the benign end from the atypical end.

Here a positive stain is often the reassuring result, and a negative stain is what raises concern. That does not make a negative stain proof of cancer. It means the pathologist has to weigh cell shape and other stains to decide between atypia and carcinoma in situ.

A negative lesion can still show a few positive cells, which are normal cells trapped within it.⁹ So the pattern and amount matter, which is why reports describe them. On papillary lesions, some labs call more than 20% patchy staining “high.”¹⁰

A strongly positive stain supports a benign overgrowth but does not exclude a separate abnormal area elsewhere in the same biopsy. A core biopsy samples only a small piece of the lesion, so the final diagnosis rests on the whole picture, including imaging.

The result shapes next steps. A benign result supported by CK5/6 usually means routine follow-up, while an atypical result often leads to a surgical excision to check nearby tissue. It is reasonable to ask whether the imaging and biopsy findings agree, and whether further surgery is recommended and why.

CK5/6 Positive in a Prostate Biopsy

Normal prostate glands have a layer of basal cells, and prostate cancer glands lose it. So in studies of prostate needle biopsies, CK5/6 did not stain cancerous glands.¹¹ It picked up 97% of benign glands at a strict threshold, far better than an older stain.¹² Benign look-alikes such as atrophy all stained, while cancers, including hormone-treated ones, were negative.¹³

A tiny focus of small glands on a needle biopsy can be hard to call by shape alone. Finding basal cells around a suspicious gland is strong evidence that the gland is benign.

The stain is often combined with p63 and a cancer marker called AMACR on one slide.¹⁴ A gland positive for AMACR but missing basal-cell staining supports cancer in the right context.¹⁵ Precancerous changes show broken, “checkerboard” basal staining.¹⁶

Positive staining is not a full all-clear. Basal cells in one gland speak only for that gland, and cancer can sit in a neighboring gland on the same slide. Pathologists therefore read the stain together with the pattern across the whole area.

The Gleason score and the core-by-core list carry the actual diagnosis. It is worth asking which cores the stain was used on.

CK5/6 Positive in the Lung or Chest Lining

Lung cancers of the non-small cell kind are mainly squamous cell carcinoma or adenocarcinoma, and treatment differs. CK5/6 is usually positive in squamous lung cancer and usually negative in adenocarcinoma.¹⁷ It does miss some squamous cancers, catching somewhere between about half and nearly all in different labs.¹⁸¹⁹ So it is paired with p63 and TTF-1 to settle the type.²⁰ A positive result points to squamous type with high reliability, about 96–98% in studies.²¹

The type matters because some targeted drugs are chosen or avoided by type, and a CK5/6 result helps the oncologist choose molecular tests. Lung biopsies are often tiny samples taken through a bronchoscope or needle, so there may be too little tissue for many tests. A quick stain that answers the type question leaves more tissue for molecular testing.

A negative result does not rule out squamous cancer, since some squamous tumors fail to stain. The pathologist then relies on p63 and TTF-1 and on how the cells look. Rarely, a tumor stays unclear and is called non-small cell carcinoma, not otherwise specified.

Mesothelioma is cancer of the thin lining around the lungs or abdomen. All mesotheliomas stained for CK5/6 while lung adenocarcinomas did not,²² so it is one of a standard group with calretinin, WT-1, D2-40 and BAP1.²³ Some ovarian cancers spreading to the abdomen also stain, so a panel is needed.²⁴

If cancer is found somewhere without a clear origin, stains help guess where it began. CK5/6 and p63 both positive strongly suggest a squamous origin,²⁵ and sites like lung, head and neck, cervix or skin are then examined.

CK5/6 Positive in an Invasive Breast Cancer

Triple-negative breast cancer lacks estrogen, progesterone and HER2 receptors. About half of triple-negative cancers stain for CK5/6.²⁶ Triple-negative tumors positive for CK5/6 or EGFR are called basal-like,²⁷ and these tend to be high-grade, fast-growing tumors.²⁸

Basal-like is a lab description of how the tumor’s cells resemble the basal layer of normal breast ducts, not a separate stage or disease. Stage, meaning size and spread, is still the main factor in the outlook. The label is partly a research category, and not every pathology report uses it.

Links to outlook are mixed. In one group of triple-negative patients, CK5/6 positive tumors had lower five-year mortality, a finding still needing confirmation.²⁹ In HER2-positive cancers, however, at least 10% CK5/6 staining was linked to worse survival and earlier failure of trastuzumab treatment.³⁰ The lab cutoffs for calling a tumor positive differ between studies, and a finding in a group does not predict what will happen to one person, so the marker is not used to make decisions on its own.

Triple-negative cancers do not respond to hormone-blocking or HER2-targeted drugs, so chemotherapy is the usual backbone of treatment. Fast-growing tumors often respond well to chemotherapy even though they are described as aggressive.

Useful questions for your oncologist: Does the basal-like label change my treatment plan? Are there clinical trials for my subtype? How do stage and grade weigh against this marker? Should genomic testing be done?

CK5/6 Positive in Bladder and Other Cancers

In normal bladder lining and low-grade tumors, CK5/6 stains only the bottom layer.³¹ In higher-grade tumors the basal layer may be lost and stain negative.³² When staining spreads through the upper layers of a tumor, pathologists take it as a sign of squamous or basal features.

In muscle-invasive bladder cancer, CK5/6 marks the basal subtype and GATA3 the luminal.³³ These subtypes describe how the tumor behaves biologically and may influence chemotherapy discussions, but they are not yet a standard reason to change treatment everywhere. CK5/6 matches squamous features in 96% of such tumors.³⁴

Over 95% of squamous cancers from any site are positive.³⁵ Basal cell skin cancer, thymoma and salivary tumors are usually positive as well.³⁶ In womb-lining cancer, though, losing CK5/6 was linked to more aggressive disease.³⁷

Because many tissues contain squamous or basal cells, a positive stain can appear in benign conditions too, for example in areas of squamous change. The meaning comes from what the pathologist is trying to classify, so it should be read alongside the final diagnosis.

What to Do With Your Result

Ask for a copy of the full pathology report, not just the summary. Find the organ and the final diagnosis line first. Then ask what question the CK5/6 stain was meant to answer. A second pathology opinion is reasonable for difficult or borderline breast and prostate lesions.

Before your appointment, write down the stains listed and their results. Percentages on the report describe how many cells stained, not your odds of cancer. Ask whether the result is benign, precancer or cancer, how it affects treatment or follow-up, and when results from any extra tests will arrive.

A second review means sending your existing slides or tissue block to another pathologist, so you usually do not need a new biopsy. Ask the pathology department of the first lab how to request the slides, and ask your doctor’s office to help with the transfer. Ask for the second report to be sent to the doctor who will make treatment decisions.

Sometimes extra stains are added days after the first report, so a result may be updated. If your report says the stains are pending, ask your doctor’s office when to expect the final version before deciding what the result means.